InvestSMART

G8 Education Limited (ASX:GEM)

ALERT: Price-sensitive ASX Announcement for GEM
Current share price for GEM : $0.133 -0.328 (-71.20%)+
Announcement
Release
23 Feb 2026 8:25AM
Price at Release
$0.460
Full Release
download
Summary
Memphasys Limited's FY2025 report outlines a challenging financial year with a net loss of $4.94 million, up 11% from the previous year due to increased operating expenses and reduced revenue. The company continued to invest in its core projects, achieving significant milestones like the CE Mark application for the Felix™ System, a key advancement in reproductive technology. Despite the financial losses, Memphasys focused on strategic development, including clinical trials and international market expansion for the Felix™ System, aiming for regulatory approval and commercial growth in major global markets.
Key Points
  • Net loss for FY2025 was $4.94 million, compared to $4.44 million in FY2024.
  • Total revenue decreased by 47% from the previous year.
  • Significant investment in the Felix™ System, leading to a CE Mark application.
  • Increased focus on global market expansion for reproductive technology.
  • The financial year ended with total assets of $11.02 million and total liabilities of $5.65 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.